Iovance Biotherapeutics (IOVA) EBIT (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly EBIT of -$81.0 million for Q1 2026, up 33.14% year-over-year from -$60.9 million in Q1 2025, and down 10.32% quarter-over-quarter from -$73.5 million in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) EBIT (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported EBIT for 17 consecutive years, with -$81.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 33.14% year-over-year to -$81.0 million; the TTM figure through Mar 2026 stood at -$363.2 million (up 8.93% YoY), while the FY2025 annual figure was -$403.4 million, down 2.04% from the prior year.
- EBIT slipped to -$81.0 million in Q1 2026 per IOVA's latest filing, from -$73.5 million in the prior quarter.
- Across five years, EBIT topped out at -$73.5 million in Q4 2025 and bottomed at -$121.3 million in Q4 2023.
- Historically, EBIT has averaged -$102.3 million across 5 years, with a median of -$101.9 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT fell 22.48% — and 2026, when it surged 33.14%.
- Iovance Biotherapeutics' EBIT stood at -$107.0 million in 2022, then fell by 13.29% to -$121.3 million in 2023, then grew by 28.6% to -$86.6 million in 2024, then rose by 15.15% to -$73.5 million in 2025, then decreased by 10.32% to -$81.0 million in 2026.
- Business Quant data shows IOVA's EBIT at -$81.0 million in Q1 2026, -$73.5 million in Q4 2025, and -$94.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | -51.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -51.91 Mn |
| Mar 31, 2026 | -81.04 Mn |
| Dec 31, 2025 | -73.46 Mn |
| Sep 30, 2025 | -94.90 Mn |
| Jun 30, 2025 | -113.77 Mn |
| Mar 31, 2025 | -121.22 Mn |
| Dec 31, 2024 | -86.58 Mn |
| Sep 30, 2024 | -89.07 Mn |
| Jun 30, 2024 | -101.91 Mn |
| Mar 31, 2024 | -117.72 Mn |
| Dec 31, 2023 | -121.26 Mn |
| Sep 30, 2023 | -118.36 Mn |
| Jun 30, 2023 | -110.09 Mn |
| Mar 31, 2023 | -110.86 Mn |
| Dec 31, 2022 | -107.04 Mn |
| Sep 30, 2022 | -100.40 Mn |
| Jun 30, 2022 | -99.73 Mn |
| Mar 31, 2022 | -91.71 Mn |
| Dec 31, 2021 | -99.47 Mn |
| Sep 30, 2021 | -86.24 Mn |